Literature DB >> 22547218

The treatment of severe hepatitis B virus reactivation after chemotherapy.

Xing Li, Yan-Fang Xing, Qu Lin, Min Dong, Xiang-Bo Wan, Xiang-Yuan Wu.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22547218     DOI： 10.1038/nrclinonc.2012.1-c1

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

Review 1.  Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer.

Authors:  Harrys A Torres; Marta Davila
Journal:  Nat Rev Clin Oncol       Date:  2012-01-24       Impact factor: 66.675

Review 2.  Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.

Authors:  Winnie Yeo; Philip J Johnson
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

3.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

Review 4.  EASL Clinical Practice Guidelines: management of chronic hepatitis B.

Authors: 
Journal:  J Hepatol       Date:  2008-10-29       Impact factor: 25.083

5.  Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection.

Authors:  Nami Mori; Fumitaka Suzuki; Yusuke Kawamura; Hitomi Sezaki; Tetsuya Hosaka; Norio Akuta; Masahiro Kobayashi; Satoshi Saito; Yoshiyuki Suzuki; Yasuji Arase; Kenji Ikeda; Mariko Kobayashi; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2012-02-29       Impact factor: 7.527

6.  Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports.

Authors:  A M Evens; B D Jovanovic; Y-C Su; D W Raisch; D Ganger; S M Belknap; M-S Dai; B-C C Chiu; B Fintel; Y Cheng; S-S Chuang; M-Y Lee; T-Y Chen; S-F Lin; C-Y Kuo
Journal:  Ann Oncol       Date:  2010-11-29       Impact factor: 32.976

7.  Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma.

Authors:  Xing Li; Qu Lin; Min Dong; Jing-Yun Wen; Li Wei; Xiao-Kun Ma; Zhan-Hong Chen; Xiang-Yuan Wu
Journal:  Leuk Lymphoma       Date:  2010-09

8.  Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience.

Authors:  H L Tillmann; J Hadem; L Leifeld; K Zachou; A Canbay; C Eisenbach; I Graziadei; J Encke; H Schmidt; W Vogel; A Schneider; U Spengler; G Gerken; G N Dalekos; H Wedemeyer; M P Manns
Journal:  J Viral Hepat       Date:  2006-04       Impact factor: 3.728

9.  Acute liver failure: Summary of a workshop.

Authors:  William M Lee; Robert H Squires; Scott L Nyberg; Edward Doo; Jay H Hoofnagle
Journal:  Hepatology       Date:  2008-04       Impact factor: 17.425
  9 in total
  1 in total

1.  An optimized antiviral modification strategy for prevention of hepatitis B reactivation in patients undergoing prophylactic lamivudine and chemotherapy: a pilot study.

Authors:  Xiang-Yuan Wu; Xing Li; Zhan-Hong Chen; Jing-Yun Wen; Qu Lin; Yan-Fang Xing; Min Dong; Li Wei; Tian-Tian Wang; Jie Chen; Ze-Xiao Lin; Xiang-bo Wan; Dan-Yun Ruan; Xiao-Kun Ma
Journal:  Tumour Biol       Date:  2012-12-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.